Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3748 |
Name | esophagus squamous cell carcinoma |
Definition | An esophageal carcinoma that derives_from epithelial squamous cells located_in the esophagus. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer esophageal cancer esophageal carcinoma esophagus squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA E545K | LY294002 | esophagus squamous cell carcinoma | sensitive | detail... |
TP53 mutant | Adavosertib + Radiotherapy | esophagus squamous cell carcinoma | sensitive | detail... |
TP53 mutant | Adavosertib | esophagus squamous cell carcinoma | predicted - sensitive | detail... |
RET fusion | Selpercatinib | esophagus squamous cell carcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | esophagus squamous cell carcinoma | sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | esophagus squamous cell carcinoma | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | esophagus squamous cell carcinoma | sensitive | detail... |
MLH1 negative | Pembrolizumab | esophagus squamous cell carcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | esophagus squamous cell carcinoma | sensitive | detail... |
MLH1 negative | Ipilimumab + Nivolumab | esophagus squamous cell carcinoma | sensitive | detail... |
MLH1 negative | Fluorouracil + Nivolumab + Oxaliplatin | esophagus squamous cell carcinoma | sensitive | detail... |
MSH6 negative | Fluorouracil + Nivolumab + Oxaliplatin | esophagus squamous cell carcinoma | sensitive | detail... |
MLH1 negative | Capecitabine + Nivolumab + Oxaliplatin | esophagus squamous cell carcinoma | sensitive | detail... |
MSH6 negative | Capecitabine + Nivolumab + Oxaliplatin | esophagus squamous cell carcinoma | sensitive | detail... |
MLH1 negative | Fluorouracil + Oxaliplatin + Pembrolizumab | esophagus squamous cell carcinoma | sensitive | detail... |
MSH6 negative | Fluorouracil + Oxaliplatin + Pembrolizumab | esophagus squamous cell carcinoma | sensitive | detail... |
MLH1 negative | Capecitabine + Oxaliplatin + Pembrolizumab | esophagus squamous cell carcinoma | sensitive | detail... |
MSH6 negative | Capecitabine + Oxaliplatin + Pembrolizumab | esophagus squamous cell carcinoma | sensitive | detail... |
MSH6 negative | Ipilimumab + Nivolumab | esophagus squamous cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 1 |
NCT01490749 | Phase I | Carboplatin + Cetuximab + Everolimus + Paclitaxel | Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer | Completed | USA | 0 |
NCT01822613 | Phase Ib/II | Docetaxel + Irinotecan + Paclitaxel Alpelisib + Elgemtumab | Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | Completed | USA | GBR | ESP | CAN | BEL | 4 |
NCT02013154 | Phase I | DKN-01 + Paclitaxel | A Study of DKN-01 in Combination With Paclitaxel | Completed | USA | 0 |
NCT02389751 | Phase I | Carboplatin Paclitaxel Ganetespib | A Study of Ganetespib in Combination With Chemoradiation | Completed | USA | 0 |
NCT02559687 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | Completed | 0 | |
NCT02564263 | Phase III | Pembrolizumab Docetaxel + Irinotecan + Paclitaxel | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | Completed | 0 | |
NCT02710396 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Genetic Predictors of Benefit to Pembrolizumab | Terminated | USA | 0 |
NCT02971956 | Phase II | Pembrolizumab | A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer | Completed | USA | 0 |
NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | GBR | 0 |
NCT03132922 | Phase I | ADP-A2M4 cells | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
NCT03143153 | Phase III | Ipilimumab + Nivolumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Nivolumab | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | AUT | AUS | 19 |
NCT03165994 | Phase II | APX005M + Carboplatin + Paclitaxel | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | Completed | USA | 0 |
NCT03189719 | Phase III | Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Pembrolizumab | First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) | Completed | USA | GBR | FRA | ESP | DEU | CAN | AUS | 19 |
NCT03212469 | Phase Ib/II | Durvalumab + Tremelimumab | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) | Active, not recruiting | FRA | 0 |
NCT03261947 | Phase II | Simurosertib | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | Completed | USA | 1 |
NCT03339843 | Phase II | Abemaciclib | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) | Active, not recruiting | FRA | BEL | 0 |
NCT03430843 | Phase III | Docetaxel Paclitaxel Tislelizumab Irinotecan | A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | 4 |
NCT03437200 | Phase II | Nivolumab Ipilimumab + Nivolumab | Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL) | Terminated | FRA | ESP | 0 |
NCT03486730 | Phase Ib/II | BT1718 | BT1718 in Patients With Advanced Solid Tumours. | Active, not recruiting | GBR | 0 |
NCT03610711 | Phase Ib/II | Nivolumab + Relatlimab Nivolumab | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) | Active, not recruiting | USA | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Recruiting | USA | 0 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Active, not recruiting | USA | FRA | ESP | 3 |
NCT03748134 | Phase III | Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Sintilimab Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Sintilimab | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma (ORIENT-15) | Completed | USA | FRA | ESP | BEL | AUS | 2 |
NCT03777813 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin | Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer (ARION) | Recruiting | FRA | 0 |
NCT03783442 | Phase III | Cisplatin Paclitaxel Tislelizumab Oxaliplatin Fluorouracil Capecitabine | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 8 |
NCT04000529 | Phase I | Spartalizumab + TNO155 Ribociclib + TNO155 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | Active, not recruiting | USA | ESP | DEU | BEL | AUS | 4 |
NCT04032704 | Phase II | Ladiratuzumab vedotin | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Active, not recruiting | USA | ITA | GBR | AUS | 2 |
NCT04047862 | Phase I | BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | Recruiting | USA | AUS | 4 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
NCT04140500 | Phase I | RO7247669 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Recruiting | USA | GBR | ESP | 10 |
NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Active, not recruiting | USA | AUS | 3 |
NCT04460937 | Phase I | Adavosertib | Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers | Active, not recruiting | USA | 0 |
NCT04543617 | Phase III | Atezolizumab Atezolizumab + Tiragolumab | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (SKYSCRAPER-07) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 19 |
NCT04550260 | Phase III | Cisplatin + Fluorouracil Capecitabine + Cisplatin Capecitabine + Cisplatin + Durvalumab Cisplatin + Durvalumab + Fluorouracil | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (KUNLUN) | Active, not recruiting | USA | FRA | ESP | CAN | BEL | 11 |
NCT04695847 | Phase I | M1231 | M1231 in Participants With Solid Tumors | Completed | USA | CAN | 0 |
NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Active, not recruiting | USA | ITA | GBR | FRA | BEL | 3 |
NCT04713891 | Phase I | KF-0210 Atezolizumab + KF-0210 | A Study of KF-0210 in Advanced Solid Tumors Patients | Unknown status | AUS | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of BND-22 in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04732494 | Phase II | BGBA1217 + Tislelizumab Tislelizumab | AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | Active, not recruiting | FRA | ESP | 4 |
NCT04785820 | Phase II | RO7121661 Nivolumab RO7247669 | A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | Active, not recruiting | ITA | GBR | FRA | ESP | 14 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Recruiting | USA | ESP | 0 |
NCT04929392 | Phase II | Carboplatin + Lenvatinib + Paclitaxel + Pembrolizumab | Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer | Active, not recruiting | USA | 0 |
NCT04939701 | Phase Ib/II | ASP0739 + Pembrolizumab ASP0739 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | Completed | USA | 0 |
NCT04949256 | Phase III | Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + Lenvatinib + Pembrolizumab Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 19 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) | Recruiting | USA | ITA | ESP | BEL | 2 |
NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 9 |
NCT05101070 | Phase Ib/II | Pembrolizumab + S-531011 Pembrolizumab S-531011 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) | Recruiting | USA | 1 |
NCT05104567 | Phase II | Cetuximab + THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | Active, not recruiting | USA | ITA | FRA | ESP | BEL | 4 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05187182 | Phase I | CA-4948 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CA-4948 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | Recruiting | USA | 0 |
NCT05208762 | Phase I | SGN-PDL1V | A Study of SGN-PDL1V in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 1 |
NCT05221320 | Phase II | Hydroxychloroquine + Ulixertinib | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Recruiting | USA | 0 |
NCT05245760 | Phase II | Tislelizumab | ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer (CRATER) | Withdrawn | USA | 0 |
NCT05319730 | Phase Ib/II | Irinotecan Paclitaxel Lenvatinib + MK-4830 + Pembrolizumab Irinotecan + MK-4830 + Pembrolizumab MK-4830 + Paclitaxel + Pembrolizumab | A Study to Evaluate Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment | Recruiting | ITA | DEU | 11 |
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS | 17 |
NCT05342636 | Phase Ib/II | Irinotecan + Pembrolizumab Irinotecan + MK-4830 + Pembrolizumab MK-4830 + Paclitaxel + Pembrolizumab Lenvatinib + MK-4830 + Pembrolizumab Irinotecan + MK-4280A MK-4280A + Paclitaxel Paclitaxel + Pembrolizumab | A Study of Combination Therapies With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer (MK-3475-06A) | Recruiting | ITA | FRA | DEU | 10 |
NCT05417321 | Phase Ib/II | HB0036 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05462873 | Phase I | QEQ278 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | 3 |
NCT05584709 | Phase I | STI-6129 | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Recruiting | ESP | BEL | 0 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05712356 | Phase II | CEND-1 + Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Paclitaxel Docetaxel CEND-1 + Docetaxel CEND-1 + Paclitaxel | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER) | Recruiting | USA | 0 |
NCT05902988 | Phase Ib/II | VLS-1488 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Recruiting | USA | 0 |
NCT05914116 | Phase Ib/II | DB-1311 | A Study of DB-1311 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05945823 | Phase II | Cisplatin + Fluorouracil + Futibatinib + Pembrolizumab Fluorouracil + Futibatinib + Leucovorin + Oxaliplatin + Pembrolizumab | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | Recruiting | USA | 0 |
NCT06034860 | Phase I | MT-8421 + Nivolumab MT-8421 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Recruiting | USA | 0 |
NCT06084481 | Phase I | ABBV-400 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Recruiting | USA | 0 |